Jupiter Biolabs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.11 Cr
as on 16-11-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.43 Cr
as on 16-11-2024
- Satisfied Charges ₹ 6.56 Cr
as on 16-11-2024
- Revenue -6.41%
(FY 2023)
- Profit 19.36%
(FY 2023)
- Ebitda 3.31%
(FY 2023)
- Net Worth 28.12%
(FY 2023)
- Total Assets 44.66%
(FY 2023)
About Jupiter Biolabs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.11 Cr.
The company currently has active open charges totaling ₹9.43 Cr. The company has closed loans amounting to ₹6.56 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rohini Pandey, Sudhir Bhosale, and Anil Patkar serve as directors at the Company.
- CIN/LLPIN
U74120MH2013PTC242884
- Company No.
242884
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Jupiter Biolabs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohini Pandey  | Director | 04-Nov-2023 | Current |
| Sudhir Bhosale | Director | 25-Sep-2018 | Current |
| Anil Patkar | Director | 03-May-2013 | Current |
Financial Performance of Jupiter Biolabs.
Jupiter Biolabs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.41% decrease. The company also saw a substantial improvement in profitability, with a 19.36% increase in profit. The company's net worth Soared by an impressive increase of 28.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jupiter Biolabs?
In 2023, Jupiter Biolabs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jupiter Analytics Private LimitedActive 8 years 10 monthsRohini Pandey and Anil Patkar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 20 Aug 2024 | ₹4.97 Cr | Open |
Others Creation Date: 29 Jun 2024 | ₹7.83 M | Open |
Others Creation Date: 09 May 2024 | ₹1.85 M | Open |
How Many Employees Work at Jupiter Biolabs?
Unlock and access historical data on people associated with Jupiter Biolabs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jupiter Biolabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jupiter Biolabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
